Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis
Liu B, Parmar A, Luo J, Dai WF, Chan KKW. Eur J Health Econ. 2025; Oct 8 [Epub ahead of print].
Liu B, Parmar A, Luo J, Dai WF, Chan KKW. Eur J Health Econ. 2025; Oct 8 [Epub ahead of print].
Hallet J, Rousseau M, Wakeam E, Myrehaug S, Meloche-Dumas L, Gombay A, Chan W, Singh S. JAMA Netw Open. 2025; 8(10):e2535125.
Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E. Cancer Med. 2025; 14(19):e71288.
Blanchette P, Reid J, Richard L, Shariff SZ, Raphael J, Earle CC, Garg AX, Kitchlu A. Nephrol Dial Transplant. 2025; gfaf191. Epub 2025 Sep 27.
Yuan B, Kabir M, He JC, Li Y, Grant B, Narine S, Welch M, Podolsky S, Liu N, Ajaj R, Zhan LJ, Fawzy A, Xu J, Zhang Y, Yu V, Xu W, Krishnan RG, Gallinger S, Chan KKW, Krzyzanowska MK, Truong T, Liu G, Grant RC. JCO Clin Cancer Inform. 2025; 9:e2500073. Epub 2025 Sep 25.
Lofters AK, Premranjith P, Gayowksy A, Khalil I, Covelli AM, Daniel JM. Cancer Causes Control. 2025; Sep 24 [Epub ahead of print].
Smith-Bindman R, Alber SA, Kwan ML, Pequeno P, Bolch WE, Bowles EJA, Greenlee RT, Stout NK, Weinmann S, Moy LM, Stewart C, Francisco M, Kofler C, Duncan JR, Ducore J, Mahendra M, Pole JD, Miglioretti DL. N Engl J Med. 2025; Sep 17 [Epub ahead of print].
Soh CH, Nguyen L, Chu A, Salim A, Abdel-Qadir H, Marwick TH. JACC Adv. 2025; 4(10 Pt 2):102129. Epub 2025 Sep 12.
Bondzi-Simpson A, Ribeiro T, Covelli A, Lofters A, Sutradhar R, Snyder RA, Clarke CN, Coburn NG, Hallet J. Ann Surg. 2025 Sep 3 [Epub ahead of print].
Ajaj R, Lau C, Gupta S, Baxter NN, Pole JD, Shaikh F, Nathan PC. EClinicalMedicine. 2025; 88:103447.